Supplementary Online Content


**eText:** Details about recurrences

**eFigure:** Dose distribution

This supplementary material has been provided by the authors to give readers additional information about their work.
Six patients in group 1 had a clinically evident recurrence, two of them 35 months after therapy and one patient 10, 11, 19 and 29 months after SDRT (mean 21.16 months), respectively. In two of these patients tumor resection was performed to achieve tumor control. One of these two patients had a recurrence even after tumor resection which required enucleation of the eye (case 31). In the other four patients enucleation was performed directly after diagnosis of the recurrence. One tumor was T1, one T2, two T3 and two T4 UM according to the TNM size classification. One patient had UM TNM stage IIA, three IIB, one IIIA and one IIIB. Two UM were posteriorly situated, two peripherally, one anteriorly and one extended from the periphery to the posterior pole. Two tumors revealed ciliary body involvement. Two tumors showed mixed cell type, one epithelioid cell type and in three tumors cell type was not known. Two of the patients with recurrences had clinically evident metastases at the end of the follow-up.
eFigure. Dose distribution (%) with delivery of 25 Gy to the 50% surrounding isodose, colored dose levels show the 10%, 20%, 50%, 80%, 90% isodoses.